Blockchain Registration Transaction Record

TransCode Submits IND Amendment for Phase 2a Cancer Trial Targeting Metastasis

TransCode Therapeutics submits IND amendment for Phase 2a trial of TTX-MC138 targeting metastatic colorectal cancer. Trial to enroll ctDNA-positive patients in PRE-I-SPY program starting 2026.

This development matters because it represents a targeted approach to treating metastatic cancer, one of the most challenging aspects of oncology. Colorectal cancer is among the leading causes of cancer deaths worldwide, and recurrence after initial treatment remains a significant problem. By focusing on patients with circulating tumor DNA—a marker of minimal residual disease—this trial addresses the critical window when cancer might be returning but hasn't yet formed detectable tumors. The RNA-based approach targeting microRNA-10b offers a novel mechanism against metastasis that could potentially benefit not just colorectal cancer patients but those with other cancers expressing this biomarker. Successful development could lead to new treatment options for patients who currently have limited alternatives after standard therapies fail, potentially improving survival rates and quality of life for those facing advanced cancers.